Literature DB >> 22532516

Detection of fluoroquinolone-induced tendon disorders using a hospital database in Japan.

Katsuhito Hori1, Kasumi Yamakawa, Naoko Yoshida, Kazunori Ohnishi, Junichi Kawakami.   

Abstract

PURPOSE: Tendinitis and tendon rupture are well-known side effects of fluoroquinolones (FQs) in Western countries. In Japan, some case reports have been reported; however, the incidence of FQ-induced tendon disorders has not been investigated. The aims of this study were to measure the occurrence of tendon disorders associated with FQs in Japanese patients and to compare the observed risk with that of previous reports. Moreover, the observed risk in FQ-prescribed patients was compared with that in cephalosporin-prescribed patients.
METHODS: The Hamamatsu University Hospital database was examined to determine the risk of tendon disorders that occurred in all inpatients and outpatients between the first day of prescription of an oral FQ or cephalosporins to the calculated end date plus 30 days. The risk of tendon disorders, the risk ratio, and their 95% confidence intervals (CIs) were evaluated.
RESULTS: From April 1996 to December 2009, FQs were prescribed to 17 147 patients, 14 of whom had tendon disorders (risk: 0.082%, 95%CI: 0.049-0.137). The risk of a tendon disorder in FQ-prescribed patients was significantly higher than that in cephalosporin-prescribed patients (five tendon disorders in 38 517 patients, risk: 0.013%, 95%CI: 0.006-0.030, and p < 0.001). The risk ratio of a tendon disorder in FQ-prescribed patients in relation to cephalosporin-prescribed patients was 6.29 (95%CI: 2.27-17.46). A large discrepancy in the risk of tendon disorders was not observed between our findings and previous reports.
CONCLUSION: A hospital database search revealed that the risk of tendon disorders in Japanese patients administered with FQs was higher than in those administered with cephalosporins.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22532516     DOI: 10.1002/pds.3285

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  7 in total

Review 1.  Tendon Injury and Fluoroquinolone Use: A Systematic Review.

Authors:  Anne L Stephenson; Wei Wu; Daniel Cortes; Paula A Rochon
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

2.  Fluoroquinolone Use and the Risk of Collagen-Associated Adverse Events: A Systematic Review and Meta-Analysis.

Authors:  Xinyu Yu; Ding-Sheng Jiang; Jing Wang; Rui Wang; Taiqiang Chen; Kan Wang; Shiyi Cao; Xiang Wei
Journal:  Drug Saf       Date:  2019-09       Impact factor: 5.606

3.  Fluoroquinolone Antibiotics and Tendon Injury in Adolescents.

Authors:  Rachael K Ross; Alan C Kinlaw; Mackenzie M Herzog; Michele Jonsson Funk; Jeffrey S Gerber
Journal:  Pediatrics       Date:  2021-05-14       Impact factor: 9.703

4.  Association between tendon ruptures and use of fluoroquinolone, and other oral antibiotics: a 10-year retrospective study of 1 million US senior Medicare beneficiaries.

Authors:  Seo Baik; Jason Lau; Vojtech Huser; Clement J McDonald
Journal:  BMJ Open       Date:  2020-12-21       Impact factor: 2.692

5.  MIHARI project, a preceding study of MID-NET, adverse event detection database of Ministry Health of Japan-Validation study of the signal detection of adverse events of drugs using export data from EMR and medical claim data.

Authors:  Hiroshi Watanabe; Kiyoteru Takenouchi; Michio Kimura
Journal:  PLoS One       Date:  2021-09-08       Impact factor: 3.240

6.  Positive Association Between Fluoroquinolone Exposure and Tendon Disorders: A Nationwide Population-Based Cohort Study in Taiwan.

Authors:  Chun-Kai Chang; Wu-Chien Chien; Wan-Fu Hsu; Hao-Yu Chiao; Chi-Hsiang Chung; Yuan-Sheng Tzeng; Shao-Wei Huang; Kuang-Ling Ou; Chih-Chien Wang; Shyi-Jou Chen; Der-Shiun Wang
Journal:  Front Pharmacol       Date:  2022-03-21       Impact factor: 5.810

7.  A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders.

Authors:  Madalina Huruba; Andreea Farcas; Daniel Corneliu Leucuta; Camelia Bucsa; Mariana Sipos; Cristina Mogosan
Journal:  Sci Rep       Date:  2021-07-13       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.